Evaluating the Acute Glycemic Response to Different Strategies of Breaking Up Sedentary Time
NCT ID: NCT04144920
Last Updated: 2019-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2018-08-01
2019-06-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Interrupting Sitting Time During Postprandial State
NCT04590729
Breaks in Sedentary Time and Glucose Regulation in Women
NCT02135172
The Effects of Interrupting Prolonged Sitting With Intermittent Exercise on Postprandial Lipemia
NCT03856606
Examining the Effects of Morning and Evening Exercise on Glucose Regulation in Adults With Prediabetes
NCT06292000
Effects of Standing and Light-intensity Activity on Ambulatory Blood Pressure and Blood Glucose
NCT02616809
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A. Study Participants and Recruitment The target participants were sedentary office employees with impaired fasting glucose level. Participants were recruited through a study flyer via various recruitment channels (i.e., ASU faculty website, social media, word of mouth). The study flyer contains a link to a Qualtrics survey to pre-screen interested participants. All eligible participants will be scheduled for a 30-minute screening visit to assess fasting glucose level. A total of 12 sedentary and inactive employees (indicated by \>6 hrs of workplace sedentary time assessed by the activPAL device during a one-week screening period) will be enrolled to participate in a fully randomized crossover trial.
B. Study Design The study design is a crossover randomized trial with three conditions: (i) uninterrupted sitting, (ii) high-frequency and low duration (HFLD) standing breaks, and (iii) low-frequency and high duration (LFHD) standing breaks. In the interrupted sitting conditions (i.e., HFLD and LFHD), total sitting and standing time were designed to be equal in both groups. The only difference between the two conditions was on the pattern to accumulate sitting time. A common threshold for prolonged sitting time in epidemiological studies of sedentary behavior is 30 minutes of continuous sitting. In the HFLD condition, we will use half of this threshold and ask participants to interrupt their sitting time every 15 minutes using a 2.5-minute standing break. In contrast, participants will perform twice this threshold in the LFHD standing breaks where they will complete a 10-minute standing break every hour of sitting.
All possible sequence of condition were determined and organized into blocks (a total of six blocks). Each eligible participant will be randomly assigned to a block to determine the sequence that they would perform the conditions. The randomization process will involve a separate research staff preparing 40 sealed envelope that contains a block number randomly determined using a computer-generated random sequence. These envelopes will be kept in a secure cabinet by another research staff not directly involved in the project. Each participant will be blinded to the condition that they are going to perform during the visit until after their first standardized meal.
Participants will be invited to three 450-minute (7.5-hour) laboratory visits where they will be provided with a private room, a sit-stand workstation, and a desktop computer. During each laboratory visit, participants will perform their usual desk-based work activities. All visits will be scheduled one week apart. Participants will be instructed to fast overnight, and standardized breakfast and lunch meals will also be provided to control for any dietary effects on glucose level. In addition, each participant will be instructed to avoid any moderate-vigorous physical activities for at least two days and smoking cigarettes and consuming alcoholic beverages at least three days prior to each visit. Upon arrival to the lab for their first visit, participants will complete a dietary log of their last meal the previous day. They will then be instructed to replicate this meal the night prior to each visit.
C. Outcome Measures Continuous Glucose Monitors. A day prior to the first visit, participants will be fitted with a Freestyle Libre Pro (Abbott Laboratories, Chicago, IL) continuous glucose monitor by a trained researcher. The sensor will be attached to the back part of the participant's non-dominant arm and programmed to measure interstitial glucose at 15-minute intervals. The device is designed to be worn continuously for 14 days and is waterproof, lightweight (roughly the size of a quarter) and minimally obtrusive. The sensors will be attached using proper aseptic procedures and in accordance with the manufacturer's instructions. Lastly, each participant will be given instructions on how to care for the device.
At the end of the last visit, data from each sensor will be acquired using the Libre Pro reader and uploaded to an online patient repository (LibreView). Data will then be processed, and 15-minute epoch data will be downloaded into a local secure drive for further processing. Continuous glucose data corresponding to each visit date and time will be isolated using the paper logs and inspected for completeness and quality of data. Files with less than 80% of valid observation will be excluded from the succeeding analyses. Glucose incremental area under the curve (iAUC) will be calculated using the trapezoidal method along with other metrics for variability (i.e., MAGE: mean amplitude of glycemic excursions).
activPAL Device. Objective measures of sitting, standing and moving time will derived from the activPAL micro accelerometer worn on the midline of the right thigh. Participants will wear the device on two occasions: (i) for 7 consecutive days during the baseline period and (ii) for 14 consecutive days during the study. The validity and reliability of the activPAL in measuring sedentary and physical activity behaviors has been previously reported. Collected data will be processed into events of sitting, standing, or moving (i.e., stepping) using the activPAL software version 7.2.32 (PAL Technologies Ltd, Scotland, UK).
Standard Meals. Standardized meals (breakfast and lunch) will be provided in each lab visit to control for any dietary influence. Each meal are designed to provide 33% of the participant's total daily caloric needs following a typical American diet (50-60% carbohydrates, 25-35% fat, and 10-20% protein). Basal metabolic rate will be calculated for each particiapnt using Schofield's equation using a 1.5 activity factor. After calculating the required caloric content of each meal, a meal with the closest caloric value will be chosen from a list of pre-determined meal plan. A typical breakfast will be composed of a croissant, ham, cheddar cheese, cereals with milk, fruit cup, and orange juice while lunch items consisted of a ciabatta ham and cheese sandwich and orange juice. The same meal will be provided during all follow-up visits.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Block 1
Participants in this arm performed the conditions in this order: CS, HFLD, LFHD
CS: Continuous sitting
Participants were asked to sit continuously throughout the duration of the lab visit.
HFLD: HIgh frequency, low duration standing breaks
Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
LFHD: Low frequency, high duration standing breaks
Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
Block 2
Participants in this arm performed the conditions in this order: CS, LFHD, HFLD
CS: Continuous sitting
Participants were asked to sit continuously throughout the duration of the lab visit.
HFLD: HIgh frequency, low duration standing breaks
Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
LFHD: Low frequency, high duration standing breaks
Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
Block 3
Participants in this arm performed the conditions in this order: HFLD, CS, LFHD
CS: Continuous sitting
Participants were asked to sit continuously throughout the duration of the lab visit.
HFLD: HIgh frequency, low duration standing breaks
Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
LFHD: Low frequency, high duration standing breaks
Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
Block 4
Participants in this arm performed the conditions in this order: HFLD, LFHD, CS
CS: Continuous sitting
Participants were asked to sit continuously throughout the duration of the lab visit.
HFLD: HIgh frequency, low duration standing breaks
Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
LFHD: Low frequency, high duration standing breaks
Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
Block 5
Participants in this arm performed the conditions in this order: LFHD, CS, HFLD
CS: Continuous sitting
Participants were asked to sit continuously throughout the duration of the lab visit.
HFLD: HIgh frequency, low duration standing breaks
Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
LFHD: Low frequency, high duration standing breaks
Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
Block 6
Participants in this arm performed the conditions in this order: LFHD, HFLD, CS
CS: Continuous sitting
Participants were asked to sit continuously throughout the duration of the lab visit.
HFLD: HIgh frequency, low duration standing breaks
Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
LFHD: Low frequency, high duration standing breaks
Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CS: Continuous sitting
Participants were asked to sit continuously throughout the duration of the lab visit.
HFLD: HIgh frequency, low duration standing breaks
Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
LFHD: Low frequency, high duration standing breaks
Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
35 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arizona State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matthew P Buman, PhD
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona State University
Tempe, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00008450
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.